Development of a safer and more effective ibogaine analog for the treatment of opioid use disorder

Ended Cooperative Agreement Awarded Last action

Award ID
UG3DA060053
Recipient
Awarding agency
Obligated
$35,029,970

Award facts

Assistance listing
93.279 Drug Use and Addiction Research Programs
Completion date
Place of performance
New York, NY 10003, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Opioid use disorder (OUD) contributes to disability, loss of work, and over 100,000 overdose deaths per year in the U.S., emphasizing the critical need for novel medications for OUD treatment. Ibogaine, a psychoactive alkaloid from the tabernanthe iboga shrub, has shown promise in interrupting opioid dependence, reducing withdrawal symptoms, and increasing abstinence rates, even after a single treatment. However, ibogaine's cardiotoxicity and neurotoxicity pose significant barriers to its development as a drug. To leverage ibogaine's potential as an OUD therapeutic and address the risks to patient safety, we have developed a new class of synthetic iboga alkaloids, named "OXA-iboga". These compounds show no pro-arrhythmic potential, no neurotoxic effects, and enhanced efficacy in OUD-relevant preclinical behavioral assays compared to ibogaine. We propose to advance one of these compounds, GM-3009, into clinical studies by advancing GMP-manufacturing and formulation of GM-3009, completing IND-enabling toxicity studies, and determining the expected therapeutic exposures of GM-3009 and target engagement via translational biomarkers. These studies will complete the UG3 portion of this grant. If successful, the proposal will advance to the UH3 portion, which will conduct first-in-human trials, including safety and tolerability studies in healthy volunteers (a single ascending dose study, SAD) and a safety study with exploratory measures of efficacy in OUD patients undergoing opioid withdrawal. The endpoint of the entire project is generation of clinical safety and preliminary efficacy data to support subsequent phase 2 efficacy studies in OUD. The development of GM-3009 builds on decades of research on ibogaine and has the potential to deliver an innovative OUD therapy with rapid and long-term mitigation of acute and protracted withdrawal symptoms and cravings, which lead to non-medical opioid use.

Transactions

Action Obligated Date
Amendment $0
Amendment $1,851,123
Amendment $1,851,123
Amendment -$1,851,123
Amendment -$1,851,123
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $269,241
Amendment $269,241
Amendment $269,241
Amendment $269,241
Amendment $269,241
Amendment $269,241
Amendment $2,423,156
Amendment $2,423,156
Amendment $2,423,156
Amendment $2,423,156
Amendment $2,423,156
Amendment $2,423,156
Amendment $2,423,156
Amendment $15,237
Amendment $15,237
Amendment $15,237
Amendment $15,237
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $2,731,914
Amendment $2,731,914
Amendment $2,731,914
Amendment $2,731,914
Amendment $2,731,914
Original award $2,731,914
Show all 45

Quick answers

Who received award UG3DA060053?

UG3DA060053 was awarded to Gilgamesh Pharmaceuticals Inc. by National Institute on Drug Abuse (National Institutes of Health) on March 1, 2024.

How much is award UG3DA060053 worth?

$35,029,970 has been obligated on UG3DA060053.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login